
  • Services
    • THERAPEUTIC AREAS
      • Epilepsy & Seizure Disorders
      • Mental Illness
      • Neurodegenerative Disorders
      • Neurodevelopmental Disorders
      • Neuromuscular Disorders
      • Pain Models
      • Rare CNS Disorders
      • Injury and Trauma
    • CAPABILITIES
      • Microdyalisis
      • Biomarker Analysis
      • Pharmacokinetics & Pharmacodynamics (PK/PD)
      • Target Engagement
      • Electrophysiology
  • In Vivo AI Platforms
    • eCube™
    • NeuroCube®
    • PhenoCube®
    • SmartCube®
  • News & Insights
    • News
      • Press Releases
      • Upcoming Events
    • Insights
      • Publications
      • Posters
      • Research Updates
  • About
    • Leadership Team
    • Corporate Citizenship
    • Culture
    • Careers
  • Contact Us

PsychoGenics Awarded NIH HEAL Initiative Contract for Preclinical Screening Platform for Pain (PSPP)

by marcbacon | Nov 6, 2019

PARAMUS, N.J., November 6, 2019 – PGI Holding Corporation (PsychoGenics) announced that it has been awarded an Indefinite Delivery Indefinite Quantity contract by the National Institute of Neurological Disorders and Stroke (NINDS), a component of the National...

PsychoGenics Appoints Mark A. Varney, PhD as Chief Scientific Officer

by marcbacon | Nov 4, 2019

PARAMUS, N.J., November 4, 2019 – PsychoGenics Inc., announced the appointment of Mark A. Varney, Ph.D., as Chief Scientific Officer (CSO). This appointment reflects the Company’s growth in Central Nervous System (CNS) drug discovery and clinical development, and its...

Sunovion and PsychoGenics Initiate DIAMOND Phase 3 Clinical Studies for SEP-363856 in the Treatment of Adults and Adolescents with Schizophrenia

by marcbacon | Sep 27, 2019

September 27, 2019 – Marlborough, Mass., and Paramus, N.J. , – Sunovion Pharmaceuticals Inc. (Sunovion) and PsychoGenics Inc. (PsychoGenics), today announced the initiation of the DIAMOND (Developing Innovative Approaches for Mental Disorders) Phase 3 studies for...

Sunovion and PsychoGenics Announce that SEP-363856 Has Received FDA Breakthrough Therapy Designation for the Treatment of People with Schizophrenia

by marcbacon | May 10, 2019

May 10, 2019 – Marlborough, Mass., and Paramus, N.J., – Sunovion Pharmaceuticals Inc. (Sunovion) and PsychoGenics Inc. (PsychoGenics), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for SEP-363856, a novel...
Next Entries »
  • Therapeutic Areas
    • Epilepsy & Seizure Disorders
      • Preclinical Seizure Models
        • Chemical Induction Models
        • Electroshock-Induced Seizures
        • Amygdala-Induced Kindling
        • Harmaline-Induced Tremors
      • Dravet Syndrome
      • EEG Seizure
      • Angelman Syndrome
      • Rett Syndrome
      • Tuberous Sclerosis
    • Mental Illness
      • Anxiety
      • Depression
      • Schizophrenia
      • ADHD
      • Drug Abuse Liability
    • Neurodegenerative Disorders
      • Alzheimer’s Disease
      • Amyotrophic Lateral Sclerosis
      • Huntington’s Disease
      • Parkinson’s Disease
      • Spinal Muscular Atrophy (SMA)
    • Neurodevelopmental Disorders
      • ADHD Studies
      • Angelman Syndrome
      • Autism Spectrum Disorder
      • Fragile X Syndrome
      • Rett Syndrome
    • Neuromuscular Disorders
      • Amyotrophic Lateral Sclerosis
      • Charcot Marie Tooth Disease
      • Duchenne Muscular Dystrophy
      • Spinal Muscular Atrophy (SMA)
    • Pain Models
      • Acute Pain
      • Inflammatory Pain
      • Neuropathic Pain -Nerve Ligation
      • Osteoarthritis Pain Studies
      • Postoperative Pain Studies
      • PSPP Program
      • Visceral Pain
    • Rare CNS Disorders
      • Angelman Syndrome
      • Charcot Marie Tooth Disease
      • Dravet Syndrome
      • Fragile X Syndrome
      • Gaucher Disease
      • Rett Syndrome
      • Tuberous Sclerosis (TSC) Preclinical Research
    • Injury and Trauma
      • Spinal Cord Injury
      • Traumatic Brain Injury
  • Capabilities
    • Microdyalisis
    • Biomarker Analysis
      • Immunohistochemistry
      • Molecular Pharmacology
    • Pharmacokinetics & Pharmacodynamics (PK/PD)
    • Target Engagement
      • Receptor Occupancy
    • Electrophysiology
      • In vivo electrophysiology
      • Ex vivo electrophysiology
      • Compound Muscle Action Potention

Let’s Find the Right Solution Together

Our scientists are here to help you find the right model or capability for your program.

Request a Consultation

Quick Links

  • Services
  • In Vivo AI Platforms
  • News & Insights
  • About
  • Contact

Contact

Address

215 College Road
Paramus, NJ 07652

Email

info@psychogenics.com

Phone

(914) 406-8019

Fax

(914) 406-8090

© 2025 PsychoGenics Inc. All rights reserved.

  • Privacy Policy
  • Terms of Use
  • Financial Conflict of Interest Policy
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}